Download PDF
Drug Res (Stuttg)
DOI: 10.1055/a-2423-3533
Review

Tyrosine Kinase Inhibitor Induced Proteinuria – A Review

J S. Gayathri‡
1   Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Health Science Campus, Amrita Vishwa Vidyapeetham, Ponekkara, Kochi, India
,
S. Swathi Krishna‡
1   Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Health Science Campus, Amrita Vishwa Vidyapeetham, Ponekkara, Kochi, India
,
M. P. Rakesh
2   Department of Medical Oncology, Amrita Health Science Campus, Amrita Vishwa Vidyapeetham, Ponekkara, Kochi, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Tyrosine Kinase inhibitor (TKI) is a class of drugs that interfere with protein kinasesʼ signal transduction pathways through an array of inhibitory mechanisms. Tyrosine kinases (TK) have an inevitable role in downstream signal transduction and the proliferation of tumour cells. Hence, tyrosine kinase inhibitors (TKIs) are frequently employed as anti-neoplastic agents in the treatment of colon, breast, kidney, and lung cancers. They can be used as single or combination therapy with other targeted therapies. It is understood that TKIs pose a risk of developing proteinuria in some patients as it can primarily result in dysfunction of the split diaphragm, constriction or blockage of capillary lumens mediated by the basement membrane, acute interstitial nephritis, or acute tubular necrosis. This paper reviews the mechanism of action of TKIs, the pathophysiological mechanism of TKI-induced proteinuria, and its management [Fig. 1]

Keywords

TKI - proteinuria - management - adverse effect


Publication History

Received: 24 April 2024

Accepted: 07 September 2024

Article published online:
15 October 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187
    CrossrefPubMedSearch in Google Scholar
  • 2 Patterson KI, Brummer T, O’brien PM. et al. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 2009; 418: 475-489
    CrossrefPubMedSearch in Google Scholar
  • 3 Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol Res 2020; 152: 104609
    CrossrefPubMedSearch in Google Scholar
  • 4 Jiao Q, Bi L, Ren Y. et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer 2018; 17
    CrossrefPubMedSearch in Google Scholar
  • 5 Zwaans R, Thomson C. Ab initio calculations on 2-, 3-and 4- substituted quinolines in relation with their activity as protein tyrosine kinase inhibitors. Theochem 1996; 362: 51-68
    CrossrefPubMedSearch in Google Scholar
  • 6 Lamba V, Ghosh I. New directions in targeting protein kinases: Focusing upon true allosteric and bivalent inhibitors. Curr Pharm Des 2012; 18: 2936-2945
    CrossrefPubMedSearch in Google Scholar
  • 7 Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 2015; 36: 422-439
    CrossrefPubMedSearch in Google Scholar
  • 8 Wind S, Schnell D, Ebner T. et al. Clinical pharmacokinetics and pharmacodynamics of afatinib. Clin Pharmacokinet 2017; 56: 235-250
    CrossrefPubMedSearch in Google Scholar
  • 9 Jha P, Jain N, Singh AK. Imatinib-induced Stevens-Johnsons syndrome. BMJ Case Rep 2013; 2013: bcr2012007926-bcr2012007926
    CrossrefPubMedSearch in Google Scholar
  • 10 Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int 2011; 80: 1271-1277
    CrossrefPubMedSearch in Google Scholar
  • 11 Paschke L, Lincke T, Mühlberg KS. et al. Anti VEGF-TKI treatment and new renal adverse events not reported in phase III trials. Eur Thyroid J 2018; 7: 308-312
    CrossrefPubMedSearch in Google Scholar
  • 12 Prasoppokakorn T, Thanapirom K, Treeprasertsuk S. Nephrotic syndrome induced by lenvatinib treatment for hepatocellular carcinoma. Case Reports Hepatol 2022; 2022: 1-6
    CrossrefPubMedSearch in Google Scholar
  • 13 Lankhorst S, Jan Danser AH, van den Meiracker AH. Endothelin-1 and antiangiogenesis. Am J Physiol Regul Integr Comp Physiol 2016; 310: R230-R234
    CrossrefPubMedSearch in Google Scholar
  • 14 Teppo H-R, Soini Y, Karihtala P. Reactive oxygen species-mediated mechanisms of action of targeted cancer therapy. Oxid Med Cell Longev 2017; 2017: 1-11
    CrossrefPubMedSearch in Google Scholar
  • 15 Fda.gov Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf
    PubMed
  • 16 Kim A, Balis FM, Widemann BC. Sorafenib and sunitinib. Oncologist 2009; 14: 800-805
    CrossrefPubMedSearch in Google Scholar
  • 17 Managing common toxicities with new tyrosine kinase inhibitors. Cancer World Archive 2015; Available from https://archive.cancerworld.net/e-grandround/managing-common-toxicities-with-new-tyrosine-kinase-inhibitors/
    PubMed
  • 18 Culhane J, Professor P. Chair Department of Pharmaceutical Sciences School of Pharmacy College of Notre Dame of Maryland Baltimore, Li ME, BCOP Advanced Practice Pharmacist–Oncology Thomas Jefferson University Hospital Philadelphia. Targeted therapy with tyrosine kinase inhibitors. Uspharmacist.com 2008; Available from https://www.uspharmacist.com/article/targeted-therapy-with-tyrosine-kinase-inhibitors
    PubMed
  • 19 Tykerb (lapatinib) package insert. Research Triangle Park, NC: GlaxoSmithKline, 2008\
    PubMed
  • 20 Gu X, Zhang S, Zhang T. Abnormal crosstalk between endothelial cells and podocytes mediates tyrosine kinase inhibitor (TKI)-induced nephrotoxicity. Cells 2021; 10: 869
    CrossrefPubMedSearch in Google Scholar
  • 21 Louwerens M, Appelhof BC, Verloop H. et al. Fatigue and fatigue-related symptoms in patients treated for different causes of hypothyroidism. Eur J Endocrinol 2012; 167: 809-815
    CrossrefPubMedSearch in Google Scholar
  • 22 Wang Y, Fei D, Vanderlaan M. et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7: 335-345
    CrossrefPubMedSearch in Google Scholar
  • 23 Miaskowski C, Dodd M, Lee K. et al. Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J Pain Symptom Manage 2010; 40: 531-544
    CrossrefPubMedSearch in Google Scholar
  • 24 Fenton C, Patel A, Dinauer C. et al. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000; 10: 349-357
    CrossrefPubMedSearch in Google Scholar
  • 25 Louwerens M, Appelhof BC, Verloop H. et al. Fatigue and fatigue-related symptoms in patients treated for different causes of hypothyroidism. Eur J Endocrinol 2012; 167: 809-815
    CrossrefPubMedSearch in Google Scholar
  • 26 Izzedine H, Massard C, Spano JP. et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010; 46: 439-448
    CrossrefPubMedSearch in Google Scholar
  • 27 Eremina V, Sood M, Haigh J. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716
    CrossrefPubMedSearch in Google Scholar
  • 28 Kido M, Du L, Sullivan CC. et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 2005; 46: 2116-2124
    CrossrefPubMedSearch in Google Scholar
  • 29 Robert C, Soria J-C, Spatz A. et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500
    CrossrefPubMedSearch in Google Scholar
  • 30 Baek SH, Kim H, Lee J. et al. Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean J Intern Med 2014; 29: 40
    CrossrefPubMedSearch in Google Scholar
  • 31 Mendel DB, Laird AD, Xin X. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337
    PubMedSearch in Google Scholar
  • 32 Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl 2013; 11: 172-191
    CrossrefPubMedSearch in Google Scholar
  • 33 Miyake H, Harada K-I, Imai S. et al. Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib. Int J Clin Oncol 2015; 20: 796-801
    CrossrefPubMedSearch in Google Scholar
  • 34 Ochiai S, Sato Y, Minakawa A. et al. Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report. BMC Nephrol 2019; 20
    CrossrefPubMedSearch in Google Scholar
  • 35 Kumar S. 2234 sorafenib-induced nephrotic syndrome in recurrent post-transplant hepatocellular carcinoma. Am J Gastroenterol 2019; 114: S1251-S1251
    CrossrefPubMedSearch in Google Scholar
  • 36 Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017
    CrossrefPubMedSearch in Google Scholar
  • 37 Garovic VD, Wagner SJ, Petrovic LM. et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007; 22: 1136-1143
    CrossrefPubMedSearch in Google Scholar
  • 38 Fu Z, Zhang S, Gu X. et al. LDP alleviates TKI-induced proteinuria through reversing the expression of RelA in renal tissues. Front Med (Lausanne) 2023; 10
    CrossrefPubMedSearch in Google Scholar
  • 39 Zheng Y, Zhang C, Miao C. et al. ABCG2 rs2231142 polymorphism is related to sunitinib-induced toxicity in metastatic renal cell carcinoma: a systematic review. AME Med J 2017; 2: 78-78
    CrossrefPubMedSearch in Google Scholar
  • 40 de Zeeuw D, Remuzzi G, Parving H-H. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65: 2309-2320
    CrossrefPubMedSearch in Google Scholar
  • 41 Hiremath S, Fergusson D, Doucette S. et al. Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. Am J Transplant 2007; 7: 2350-2360
    CrossrefPubMedSearch in Google Scholar
  • 42 Blanco S, Bonet J, López D. et al. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int 2005; 67: S10-S14
    CrossrefPubMedSearch in Google Scholar
  • 43 Hou FF, Xie D, Zhang X. et al. Renoprotection of optimal antiproteinuric doses (ROAD) study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18: 1889-1898
    CrossrefPubMedSearch in Google Scholar
  • 44 Terada T, Noda S, Inui K-I. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther 2015; 152: 125-134
    CrossrefPubMedSearch in Google Scholar
  • 45 Santos MLC, de Brito BB, da Silva FAF. et al. Nephrotoxicity in cancer treatment: An overview. World J Clin Oncol 2020; 11: 190-204
    CrossrefPubMedSearch in Google Scholar
  • 46 Schjoedt KJ, Astrup AS, Persson F. et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia 2009; 52: 46-49
    CrossrefPubMedSearch in Google Scholar
  • 47 Burgess E, Muirhead N, Cotret D. et al. Supra Maximal Atacand Renal Trial) Investigators: Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893-900
    CrossrefPubMedSearch in Google Scholar
  • 48 Rossing K, Schjoedt KJ, Jensen BR. et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190-1198
    CrossrefPubMedSearch in Google Scholar
  • 49 Hollenberg NK, Parving H-H, Viberti G. et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921-1926
    CrossrefPubMedSearch in Google Scholar
  • 50 Aranda P, Segura J, Ruilope LM. et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005; 46: 1074-1079
    CrossrefPubMedSearch in Google Scholar
  • 51 Andersen S, Tarnow L, Rossing P. et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601-606
    CrossrefPubMedSearch in Google Scholar
  • 52 Lameire N. Nephrotoxicity of recent anti-cancer agents. Clin Kidney J 2014; 7: 11-22
    CrossrefPubMedSearch in Google Scholar